RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Cash from financing

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Dec 31, 2024-1,495+165.90%
Dec 31, 2023-562+730.43%
Dec 31, 2022-68-95.42%
Dec 31, 2021-1,478+192.51%
Dec 31, 2020-505-498.57%
Dec 31, 2019127-278.00%
Dec 31, 2018-71-204.12%
Dec 31, 201768-48.67%
Dec 31, 2016133-29.46%
Dec 31, 2015189-62.02%
Dec 31, 2014497+174.97%
Dec 31, 2013181+5.04%
Dec 31, 2012172-238.61%
Dec 31, 2011-124-129.23%
Dec 31, 2010425

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)